BioCentury
ARTICLE | Company News

AiCuris, Basilea, AstraZeneca, GlaxoSmithKline, Sanofi, Innovative Medicines Initiative infectious news

February 16, 2015 8:00 AM UTC

IMI announced the seven-year, EUR167 million ($189 million) COMBACTE-MAGNET project under the New Drugs 4 Bad Bugs program, which will partner 33 European academic sites and five companies to develop two new antibacterials to combat resistant Gram-negative bacteria. The project will focus on conducting clinical trials of MEDI3902 from AstraZeneca’s MedImmune LLC unit and AIC499 from AiCuris. MedImmune said it plans to begin a Phase II trial of MEDI3902 in 1H16. AiCuris said it plans to begin a Phase I trial of AIC499 at the end of this year or early next year. The University Medical Center Utrecht, an academic partner in the project, said GSK, Basilea and Sanofi will contribute epidemiology strategy and expertise and will organize data sources in Europe and across the New Drugs 4 Bad Bugs program. ...